A Phase 1/2 interventional study of Sublingual film containing Dexmedetomidine and Sublingual Placebo Film in Agitation,Psychomotor and Dementia, sponsored by BioXcel Therapeutics Inc. Completed at 5 sites in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by BioXcel Therapeutics Inc · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing dexmedetomidine in Psychomotor Agitation — 5 open to participants now, 5 under way, 2 of them phase 3. Dexmedetomidine · Psychomotor Agitation.
Among the 32 studies testing dexmedetomidine in Psychomotor Agitation, this one is the 12th largest by enrollment, is one of 2 that started in 2019, is the only one in phase 1/2, and was the 16th registered.
231 studies on the registry are indexed under Psychomotor Agitation; 28 are open to participants now.
Browse Psychomotor Agitation studies →5 of the 32 studies testing dexmedetomidine in Psychomotor Agitation are open now, in 3 countries. Recruiting first, the newest first:
Lone Baandrup · Sites in Denmark
Ages 18–64
Temple University · Sites in United States
Ages 18–55
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
Benha University
Ages 18+
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Ages 18+
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 20 Psychomotor Agitation studies recruiting now, 8 (40%) set no upper age limit and 7 (35%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 10 · Phase 4 11
First in 2005; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is close to the median of 100 across 188 interventional studies indexed under Psychomotor Agitation.
Median enrollment 73 across the 32 interventional studies. Of the 21 that completed or were terminated, 12 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 32 have an industry lead sponsor. The 10 most frequent:
BioXcel Therapeutics Inc is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 9 (75%) have results posted.
11 studies in Psychomotor Agitation by BioXcel Therapeutics Inc: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 11 studies in Psychomotor Agitation by BioXcel Therapeutics Inc, this one is the 6th largest by enrollment, is one of 2 that started in 2019, is the only one in phase 1/2, and was the 2nd registered.
BioXcel Therapeutics Inc’s Psychomotor Agitation studies by the year they started, since 2019.
None of the studies under way reaches primary completion within a year.
Among the 32 studies testing dexmedetomidine in Psychomotor Agitation, from their registry updates:
Among BioXcel Therapeutics Inc’s 11 in Psychomotor Agitation:
This tab as a report to print or save as PDF → With an account.
This is an adaptive Phase 1b/2 trial design. It is randomized, double-blind, placebo-controlled, multiple ascending dose study assessing efficacy, pharmacokinetics, safety and tolerability of BXCL-501 dosing in adult (65 years and older) males and females with acute agitation associated with dementia. Evaluation of 3 doses are planned.
This is a Phase 1b/2 randomized, double-blind, placebo controlled, ascending dose finding study assessing efficacy, pharmacokinetics, safety, and tolerability of BXCL501 with 3 dosing groups in adult (65 years and older) males and females with acute agitation associated with all forms of dementia. Evaluation of three (3) doses of sublingual BXCL 501 are planned. Cohort 1, Cohort 2 and Cohort 3 will be given 30µg, 60µg and 90µg dose respectively of BXCL501 or placebo. Subjects assigned to Cohort 3 will participate in a 1-week safety observation before being enrolled.
This is an adaptive design as doses selected for testing may be different from these, based upon safety reviews. Doses lower or higher may be chosen to test, up to 180µg, and additional subjects may be added to a cohort. BXCL501 films may be divided in half if needed to deliver half-dose strengths. At least 30 subjects (10 per cohort) will be enrolled at up to 3 study sites in the United States. In Part B a total of 46 subjects will receive BXCL501 40 μg or matching placebo film.
The effects of BXCL 501 on acute agitation will be assessed by the following scales: Pittsburgh Agitation Scale (PAS), the PANSS-EC (PEC), Cohen-Mansfield Agitation Inventory (CMAI), CGI-Severity for Agitation and CGI Improvement for Agitation. Adverse Events (AEs), clinical laboratory tests, ECG, and vital signs will be monitored, and all observed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1 consists of 10 patients out of whom 8 patients receive 30 Micrograms film and the remaining 2 patients receive a placebo
Drug: Sublingual film containing Dexmedetomidine · Drug: Sublingual Placebo Film
Cohort 2 consists of 10 patients out of whom 8 patients receive 60 Micrograms film and the remaining 2 patients receive a placebo. Additional 20 subjects receive 60 Micrograms or placebo.
Drug: Sublingual film containing Dexmedetomidine · Drug: Sublingual Placebo Film
Cohort 3 consists of 10 patients out of whom 8 patients receive 90 Micrograms film and the remaining 2 patients receive a placebo
Drug: Sublingual film containing Dexmedetomidine · Drug: Sublingual Placebo Film
Part B cohort consists 46 subjects receiving 40 Micrograms or placebo
Drug: Sublingual film containing Dexmedetomidine · Drug: Sublingual Placebo Film
Sublingual film containing Dexmedetomidine
Also known as: BXCL501
Sublingual placebo film that matches BXCL501
Mean Change From Baseline in Positive and Negative Syndrome Scale-Excited Component (PEC) Total Score
The change in PEC score was evaluated at 2 hours following the administration of the BXCL501 60 mcg, and BXCL501 30 mcg (for Part A) and BXCL501 40 mcg (for Part B) versus placebo. PEC is the sum of 5 subscales (poor impulse control, tension, hostility, uncooperativeness, and excitement, each subscale ranging from 1 to 7) and thus ranges from 5 to 35. Change from baseline (pre-dose) PEC total score, with negative values is in favor of improvement.
Time frame: Baseline and 2 hours post-dose
Number of Patients With Adverse Events
The safety and tolerability of single doses of BXCL501 was determined in treatment of acute agitation associated with dementia.
Time frame: Day 7 post dose
Change in Pittsburgh Agitation Scale (PAS) Total Score From Baseline
The onset and magnitude of calming effects of different doses of BXCL501 on symptoms of acute agitation associated with dementia was described as measured by the PAS. The PAS is an instrument that measured 4 behaviors namely: aberrant vocalization, motor agitation, aggressiveness and resisting to care. The patients are evaluated on a scale of 0 to 4, where 0 indicated no agitation and 4 indicated highest form of agitation. The PAS total score ranges from 0 to 16. Higher scores mean a worse outcome. Change in value of PAS total score, with negative value indicated the improvement in condition of the patients.
Time frame: Baseline and at 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 24 hours, Day 3, Day 7 post-dose
Changes in Agitation-Calmness Evaluation Scale (ACES) Score From Baseline
To evaluate the change in the total score of ACES from baseline to 8 hours post administration of 30 mcg, 60 mcg and 40 mcg compared to placebo. The ACES is a single item measure rating overall agitation and sedation which ranges from 1 to 9, where 1 indicates marked agitation, 2 - moderate agitation; 3 - mild agitation; 4 - normal behavior; 5 - mild calmness; 6 - moderate calmness; 7 - marked calmness; 8 - deep sleep; and 9 - unarousable. Change from baseline (pre-dose) ACES total score, with negative values in favor of improvement.
Time frame: Baseline and 1 hour, 2 hours, 4 hours, 8 hours post-dose
Changes in Positive and Negative Syndrome Scale (PANSS) Excited Component (PEC) Total Score From Baseline
The change in PEC score was evaluated following the administration of the BXCL501 60 mcg, and BXCL501 30 mcg (for Part A) and BXCL501 40 mcg (for Part B) versus placebo. PEC is the sum of 5 subscales (poor impulse control, tension, hostility, uncooperativeness, and excitement, each subscale ranging from 1 to 7) and thus ranges from 5 to 35. Change from baseline (pre-dose) PEC total score, with negative values is in favor of improvement.
Time frame: Baseline and at 30 minutes, 1 hour, 4 hours, 8 hours, 24 hours, Day 3 and Day 7 post-dose
Number of Patients at Each Dose Who Achieve a 40% Reduction From Baseline in PEC Total Score at 2 Hours Post-dose ("Responders")
The Number of patients who achieved a 40%reduction in total PEC score from baseline at 2 hours following administration of BXCL501 30 mcg, 60 mcg (for Part A) and BXCL501 40 mcg (for Part B) compared to placebo were evaluated. Responder defined as achieving \>= 40% reduction in PEC from baseline (pre-dose). The change from baseline in (pre-dose) PEC total score is presented for the Primary Outcome above.
Time frame: Baseline and 2 hours post-dose
Change in Clinician Global Impression of Severity (CGI-S) Agitation Score From Baseline
The CGI-S was based upon the severity of agitation. It was assessed based on the following scale: 0 = Not assessed; 1 = Normal not at all symptomatic; 2 = Minimally symptomatic- few or mild symptoms -little interference with patients functioning; 3 = Mildly symptomatic-low level of symptoms-little interference in social functioning; 4 = Moderately symptomatic-some prominent symptoms-some interference in functioning; 5 = Markedly symptomatic-significant symptoms with very substantial interference in functioning; 6 = Severely symptomatic- very marked symptoms make it difficult for patients to engage with others; 7 = Among the most extremely symptomatic patients-extreme symptoms -patient is incapacitated or highly dangerous to self or others requires extra care and supervision. The higher the score, the higher is the severity of the agitation and lesser the score, the lower the agitation. Change from baseline CGIS total score, with negative values in favor of improvement.
Time frame: Baseline and at 2 hours, and 24 hours post-dose
Clinical Global Impression - Improvement (CGI-I) Agitation Score
To evaluate the CGI-I agitation score at 30 minutes, 1 hour, 2 hours, and 8 hours after administration of 30 mcg, 60 mcg and 40 mcg of BXCL501 compared to placebo. The CGI-I scores range from 1 to 7 comprise of 0 = Not assessed (missing), 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. The lower score (1) indicated the improvement in the condition of patient and higher score (7) indicates the worsening of the condition. Straight CGI-I total score, with lower values in favor of improvement.
Time frame: 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours post-dose
Change in Cohen Mansfield Agitation Inventory (CMAI) Total Score From Baseline
To evaluate the change in Cohen Mansfield Agitation Inventory (CMAI) total score from baseline after 2 hour and on Day 7 post administration of 30 mcg, 60 mcg and 40 mcg BXCL501 compared to placebo. The CMAI is a rating which is comprised of 29 behaviors each rated on a 7-point scale of frequency. A total CMAI score is obtained by summing all the individual items, giving a range from 29 to 203. Change from baseline (pre-dose) CMAI total score, with negative values in favor of improvement in the condition of the patients.
Time frame: Baseline and at 2 Hours and Day 7 post-dose
Number of Patients With Event "Time Taken for Medication to Dissolve"
To evaluate the time taken for BXCL501 30 mcg, 60mcg, 90 mcg and 40 mcg compared to placebo to dissolve which was measured after 30 minutes of administration.
Time frame: At 30 minutes post-dose
Number of Patients Showing Negative Reaction to Sublingual Film in the Examiner's Opinion
To evaluate the number patient showing negative reactions to sublingual film by assessing the buccal at 30 minutes, 2 hours, 4 hours and 24 hours post administration of 30mcg, 60 mcg, 40 mcg and 90 mcg v/s placebo. The larger number of patients reporting negative reaction, the lesser is the reliability of the drug.
Time frame: At 30 minutes, 2 hours, 4 hours, 24 hours post dose
Part B: Change From Baseline in the Total Score of 3 Supplementary Items of Positive and Negative Syndrome Scale (PANSS)
To evaluate the change in PANSS Supplementary Items Total Score from Baseline to 2 hours post administration of 40 mcg of BXCL501 compared to placebo. PANSS Supplementary Items: The total score (sum score of anger, difficulty in delaying gratification, and affective lability) ranges from 3 to 21. The higher score indicates the worsening of the condition and lower score indicates the improvement of the condition of the patient. Change from baseline (pre-dose) PANSS Supplementary Items total score, with negative values in favor of improvement.
Time frame: Baseline and at 2 hours post-dose
The trial was conducted at 4 sites in the United States from 27 December 2019 to 24 January 2022.
| Milestone | Part A-30 mcg BXCL501 | Part A-60 mcg BXCL501 | Part A- 90 mcg BXCL501 | Part A-Placebo | Part B-40 Mcg-BXCL501 | Part B-Placebo |
|---|---|---|---|---|---|---|
| Started | 16 | 20 | 4 | 14 | 23 | 23 |
| Completed | 16 | 15 | 4 | 10 | 22 | 23 |
| Not completed | 0 | 5 | 0 | 4 | 1 | 0 |
| Withdrew: Covid 19 lockdown | 0 | 5 | 0 | 4 | 0 | 0 |
| Withdrew: Assisted living facility was closed | 0 | 0 | 0 | 0 | 1 | 0 |
The change in PEC score was evaluated at 2 hours following the administration of the BXCL501 60 mcg, and BXCL501 30 mcg (for Part A) and BXCL501 40 mcg (for Part B) versus placebo. PEC is the sum of 5 subscales (poor impulse control, tension, hostility, uncooperativeness, and excitement, each subscale ranging from 1 to 7) and thus ranges from 5 to 35. Change from baseline (pre-dose) PEC total score, with negative values is in favor of improvement.
| score on a scale | Part A-30 mcg BXCL501 | Part A-60 mcg BXCL501 | Part A-90 mcg BXCL501 | Part A-Placebo | Part B-40 Mcg-BXCL501 | Part B-Placebo |
|---|---|---|---|---|---|---|
| Mean Change From Baseline in Positive and Negative Syndrome Scale-Excited Component (PEC) Total Score | -5.4 ± 3.4 | -7.1 ± 3.8 | — | -2.9 ± 2.7 | -6.8 ± 5.1 | -1.8 ± 4.4 |
The safety and tolerability of single doses of BXCL501 was determined in treatment of acute agitation associated with dementia.
| Participants | Part A-30 mcg BXCL501 | Part A-60 mcg BXCL501 | Part A- 90 mcg BXCL501 | Part A-Placebo | Part B-40 Mcg-BXCL501 | Part B-Placebo |
|---|---|---|---|---|---|---|
| Number of Patients With Adverse Events | 11 | 14 | 4 | 0 | 12 | 2 |
The onset and magnitude of calming effects of different doses of BXCL501 on symptoms of acute agitation associated with dementia was described as measured by the PAS. The PAS is an instrument that measured 4 behaviors namely: aberrant vocalization, motor agitation, aggressiveness and resisting to care. The patients are evaluated on a scale of 0 to 4, where 0 indicated no agitation and 4 indicated highest form of agitation. The PAS total score ranges from 0 to 16. Higher scores mean a worse outcome. Change in value of PAS total score, with negative value indicated the improvement in condition of the patients.
| score on a scale | Part A-30 mcg BXCL501 | Part A-60 mcg BXCL501 | Part A-90 mcg BXCL501 | Part A-Placebo | Part B-40 Mcg-BXCL501 | Part B-Placebo |
|---|---|---|---|---|---|---|
| 30 minutes | -1.3 ± 1.2 | -1.6 ± 1.7 | — | -1.3 ± 1.6 | -1.3 ± 2.8 | -0.7 ± 0.9 |
| 1 hour | -2.5 ± 1.8 | -4.0 ± 2.2 | — | -2.1 ± 1.8 | -4.7 ± 3.2 | -1.6 ± 2.0 |
| 2 hours | -3.9 ± 2.4 | -5.8 ± 2.1 | — | -2.6 ± 2.4 | -5.4 ± 3.4 | -1.8 ± 2.7 |
| 4 hours | -4.7 ± 3.1 | -6.4 ± 1.3 | — | -3.3 ± 2.8 | -5.2 ± 3.7 | -2.1 ± 2.8 |
| 8 hours | -4.4 ± 3.2 | -6.2 ± 1.7 | — | -3.1 ± 2.0 | -4.1 ± 3.5 | -2.3 ± 2.7 |
| 24 hours | -4.3 ± 2.8 | -4.9 ± 2.1 | — | -3.9 ± 2.4 | -2.0 ± 2.2 | -1.8 ± 2.4 |
| Day 3 | -3.9 ± 3.4 | -4.9 ± 2.4 | — | -3.7 ± 3.4 | -2.0 ± 1.9 | -1.9 ± 1.6 |
| Day 7 | -3.9 ± 3.1 | -4.3 ± 2.3 | — | -3.3 ± 2.7 | -2.6 ± 3.3 | -1.1 ± 1.4 |
To evaluate the change in the total score of ACES from baseline to 8 hours post administration of 30 mcg, 60 mcg and 40 mcg compared to placebo. The ACES is a single item measure rating overall agitation and sedation which ranges from 1 to 9, where 1 indicates marked agitation, 2 - moderate agitation; 3 - mild agitation; 4 - normal behavior; 5 - mild calmness; 6 - moderate calmness; 7 - marked calmness; 8 - deep sleep; and 9 - unarousable. Change from baseline (pre-dose) ACES total score, with negative values in favor of improvement.
| score on a scale | Part A-30 mcg BXCL501 | Part A-60 mcg BXCL501 | Part A-90 mcg BXCL501 | Part A-Placebo | Part B-40 Mcg-BXCL501 | Part B-Placebo |
|---|---|---|---|---|---|---|
| 1 hour | 0.6 ± 0.6 | 1.1 ± 0.7 | — | 0.5 ± 0.5 | 1.8 ± 1.6 | 0.4 ± 0.8 |
| 2 hours | 0.9 ± 1.0 | 2.7 ± 1.6 | — | 0.9 ± 0.9 | 2.5 ± 1.9 | 0.7 ± 1.3 |
| 4 hours | 1.3 ± 1.0 | 2.7 ± 1.2 | — | 0.9 ± 1.1 | 2.4 ± 2.0 | 1.0 ± 1.4 |
| 8 hours | 1.4 ± 1.1 | 2.2 ± 0.9 | — | 0.9 ± 0.8 | 1.5 ± 1.5 | 1.0 ± 1.2 |
The change in PEC score was evaluated following the administration of the BXCL501 60 mcg, and BXCL501 30 mcg (for Part A) and BXCL501 40 mcg (for Part B) versus placebo. PEC is the sum of 5 subscales (poor impulse control, tension, hostility, uncooperativeness, and excitement, each subscale ranging from 1 to 7) and thus ranges from 5 to 35. Change from baseline (pre-dose) PEC total score, with negative values is in favor of improvement.
| score on a scale | Part A-30 mcg BXCL501 | Part A-60 mcg BXCL501 | Part A-90 mcg BXCL501 | Part A-Placebo | Part B-40 Mcg-BXCL501 | Part B-Placebo |
|---|---|---|---|---|---|---|
| 30 minutes | -2.2 ± 1.6 | -1.7 ± 2.2 | — | -0.6 ± 1.4 | -1.0 ± 2.4 | -1.0 ± 1.7 |
| 1 hours | -3.6 ± 1.9 | -5.4 ± 3.6 | — | -2.3 ± 2.0 | -5.7 ± 4.4 | -1.9 ± 3.2 |
| 4 hours | -6.8 ± 4.4 | -8.1 ± 2.5 | — | -4.1 ± 3.6 | -6.5 ± 4.5 | -2.8 ± 4.8 |
| 8 hours | -7.1 ± 4.6 | -8.8 ± 3.1 | — | -4.6 ± 3.3 | -5.0 ± 4.3 | -3.2 ± 4.7 |
| Day 2; 24 hours | -5.7 ± 4.0 | -6.0 ± 3.8 | — | -4.3 ± 3.3 | -3.4 ± 3.7 | -2.4 ± 4.0 |
| Day 3 | -5.3 ± 5.0 | -5.9 ± 4.2 | — | -3.9 ± 3.7 | -3.2 ± 3.3 | -1.8 ± 2.7 |
| Day 7 | -4.9 ± 3.9 | -4.6 ± 3.9 | — | -3.4 ± 4.4 | -2.5 ± 4.1 | -1.5 ± 1.5 |
The Number of patients who achieved a 40%reduction in total PEC score from baseline at 2 hours following administration of BXCL501 30 mcg, 60 mcg (for Part A) and BXCL501 40 mcg (for Part B) compared to placebo were evaluated. Responder defined as achieving \>= 40% reduction in PEC from baseline (pre-dose). The change from baseline in (pre-dose) PEC total score is presented for the Primary Outcome above.
| Participants | Part A-30 mcg BXCL501 | Part A-60 mcg BXCL501 | Part A-90 mcg BXCL501 | Part A-Placebo | Part B-40 Mcg-BXCL501 | Part B-Placebo |
|---|---|---|---|---|---|---|
| Number of Patients at Each Dose Who Achieve a 40% Reduction From Baseline in PEC Total Score at 2 Hours Post-dose ("Responders") | 4 | 14 | — | 1 | 9 | 2 |
The CGI-S was based upon the severity of agitation. It was assessed based on the following scale: 0 = Not assessed; 1 = Normal not at all symptomatic; 2 = Minimally symptomatic- few or mild symptoms -little interference with patients functioning; 3 = Mildly symptomatic-low level of symptoms-little interference in social functioning; 4 = Moderately symptomatic-some prominent symptoms-some interference in functioning; 5 = Markedly symptomatic-significant symptoms with very substantial interference in functioning; 6 = Severely symptomatic- very marked symptoms make it difficult for patients to engage with others; 7 = Among the most extremely symptomatic patients-extreme symptoms -patient is incapacitated or highly dangerous to self or others requires extra care and supervision. The higher the score, the higher is the severity of the agitation and lesser the score, the lower the agitation. Change from baseline CGIS total score, with negative values in favor of improvement.
| score on a scale | Part A-30 mcg BXCL501 | Part A-60 mcg BXCL501 | Part A-90 mcg BXCL501 | Part A-Placebo | Part B-40 Mcg-BXCL501 | Part B-Placebo |
|---|---|---|---|---|---|---|
| 2 hours | -1.3 ± 0.8 | -2.1 ± 0.9 | — | -0.9 ± 0.9 | -2.2 ± 1.3 | -0.7 ± 1.0 |
| 24 hours | -1.4 ± 1.1 | -1.6 ± 0.9 | — | -1.2 ± 1.1 | -1.2 ± 1.1 | -0.7 ± 1.2 |
To evaluate the CGI-I agitation score at 30 minutes, 1 hour, 2 hours, and 8 hours after administration of 30 mcg, 60 mcg and 40 mcg of BXCL501 compared to placebo. The CGI-I scores range from 1 to 7 comprise of 0 = Not assessed (missing), 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. The lower score (1) indicated the improvement in the condition of patient and higher score (7) indicates the worsening of the condition. Straight CGI-I total score, with lower values in favor of improvement.
| score on a scale | Part A-30 mcg BXCL501 | Part A-60 mcg BXCL501 | Part A-90 mcg BXCL501 | Part A-Placebo | Part B-40 Mcg-BXCL501 | Part B-Placebo |
|---|---|---|---|---|---|---|
| 30 minutes | 3.3 ± 0.2 | 3.4 ± 0.2 | — | 3.5 ± 0.2 | 3.5 ± 0.1 | 3.7 ± 0.1 |
| 1 hour | 3.0 ± 0.2 | 2.6 ± 0.2 | — | 3.3 ± 0.2 | 2.5 ± 0.2 | 3.5 ± 0.2 |
| 2 hours | 2.4 ± 0.2 | 1.6 ± 0.2 | — | 3.2 ± 0.2 | 1.9 ± 0.2 | 3.6 ± 0.2 |
| 4 hours | 2.4 ± 0.3 | 1.5 ± 0.2 | — | 3.0 ± 0.3 | 2.0 ± 0.3 | 3.3 ± 0.3 |
| 8 hours | 2.3 ± 0.2 | 1.4 ± 0.2 | — | 3.0 ± 0.2 | 2.5 ± 0.3 | 3.5 ± 0.3 |
To evaluate the change in Cohen Mansfield Agitation Inventory (CMAI) total score from baseline after 2 hour and on Day 7 post administration of 30 mcg, 60 mcg and 40 mcg BXCL501 compared to placebo. The CMAI is a rating which is comprised of 29 behaviors each rated on a 7-point scale of frequency. A total CMAI score is obtained by summing all the individual items, giving a range from 29 to 203. Change from baseline (pre-dose) CMAI total score, with negative values in favor of improvement in the condition of the patients.
| score on a scale | Part A-30 mcg BXCL501 | Part A-60 mcg BXCL501 | Part A-90 mcg BXCL501 | Part A-Placebo | Part B-40 Mcg-BXCL501 | Part B-Placebo |
|---|---|---|---|---|---|---|
| 2 hours | -8.9 ± 5.1 | -14.7 ± 9.8 | — | 1.6 ± 4.5 | -17.9 ± 22.7 | -5.7 ± 14.0 |
| Day 7 | -5.9 ± 4.3 | -6.6 ± 6.7 | — | 0.4 ± 9.8 | -6.9 ± 17.7 | -1.4 ± 4.5 |
To evaluate the time taken for BXCL501 30 mcg, 60mcg, 90 mcg and 40 mcg compared to placebo to dissolve which was measured after 30 minutes of administration.
| Participants | Part A-30 mcg BXCL501 | Part A-60 mcg BXCL501 | Part A- 90 mcg BXCL501 | Part A-Placebo | Part B-40 Mcg-BXCL501 | Part B-Placebo |
|---|---|---|---|---|---|---|
| 1- 30 seconds | 0 | 0 | 0 | 0 | 0 | 0 |
| 31- 59 seconds | 0 | 0 | 0 | 0 | 0 | 2 |
| 1- 2 minutes | 10 | 8 | 2 | 8 | 12 | 10 |
| 3+ minutes | 6 | 12 | 2 | 6 | 11 | 11 |
To evaluate the number patient showing negative reactions to sublingual film by assessing the buccal at 30 minutes, 2 hours, 4 hours and 24 hours post administration of 30mcg, 60 mcg, 40 mcg and 90 mcg v/s placebo. The larger number of patients reporting negative reaction, the lesser is the reliability of the drug.
| Participants | Part A-30 mcg BXCL501 | Part A-60 mcg BXCL501 | Part A- 90 mcg BXCL501 | Part A-Placebo | Part B-40 Mcg-BXCL501 | Part B-Placebo |
|---|---|---|---|---|---|---|
| 30 minutes Post dose | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 hours post dose | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 hours post dose | 0 | 0 | 0 | 0 | 0 | 0 |
| 24 hours post dose | 0 | 0 | 0 | 0 | 0 | 0 |
To evaluate the change in PANSS Supplementary Items Total Score from Baseline to 2 hours post administration of 40 mcg of BXCL501 compared to placebo. PANSS Supplementary Items: The total score (sum score of anger, difficulty in delaying gratification, and affective lability) ranges from 3 to 21. The higher score indicates the worsening of the condition and lower score indicates the improvement of the condition of the patient. Change from baseline (pre-dose) PANSS Supplementary Items total score, with negative values in favor of improvement.
| score on a scale | Part B-40 Mcg-BXCL501 | Part B-Placebo |
|---|---|---|
| Part B: Change From Baseline in the Total Score of 3 Supplementary Items of Positive and Negative Syndrome Scale (PANSS) | -3.7 ± 2.9 | -0.6 ± 2.3 |
Collected over Day 7 post-dose. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A-30 mcg BXCL501 | 0/16 (0%) | 0/16 (0%) | 11/16 (68.8%) |
| Part A-60 mcg BXCL501 | 0/20 (0%) | 0/20 (0%) | 14/20 (70%) |
| Part A- 90 mcg BXCL501 | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Part A-Placebo | 0/14 (0%) | 0/14 (0%) | 0/14 (0%) |
| Part B-40 Mcg-BXCL501 | 1/23 (4.3%) | 1/23 (4.3%) | 12/23 (52.2%) |
| Part B-Placebo | 0/23 (0%) | 0/23 (0%) | 2/23 (8.7%) |
| Event | Part A-30 mcg BXCL501 | Part A-60 mcg BXCL501 | Part A- 90 mcg BXCL501 | Part A-Placebo | Part B-40 Mcg-BXCL501 | Part B-Placebo |
|---|---|---|---|---|---|---|
| SepsisInfections and infestations | 0/16 | 0/20 | 0/4 | 0/14 | 1/23 | 0/23 |
| HypernatraemiaMetabolism and nutrition disorders | 0/16 | 0/20 | 0/4 | 0/14 | 1/23 | 0/23 |
| Event | Part A-30 mcg BXCL501 | Part A-60 mcg BXCL501 | Part A- 90 mcg BXCL501 | Part A-Placebo | Part B-40 Mcg-BXCL501 | Part B-Placebo |
|---|---|---|---|---|---|---|
| SomnolenceNervous system disorders | 9/16 | 12/20 | 3/4 | 0/14 | 8/23 | 2/23 |
| Orthostatic hypotensionVascular disorders | 1/16 | 1/20 | 3/4 | 0/14 | 0/23 | 0/23 |
| DizzinessNervous system disorders | 1/16 | 1/20 | 2/4 | 0/14 | 1/23 | 0/23 |
| HypotensionVascular disorders | 0/16 | 2/20 | 1/4 | 0/14 | 2/23 | 0/23 |
| DehydrationMetabolism and nutrition disorders | 0/16 | 0/20 | 0/4 | 0/14 | 3/23 | 0/23 |
| HeadacheNervous system disorders | 0/16 | 1/20 | 0/4 | 0/14 | 0/23 | 0/23 |
| BradycardiaCardiac disorders | 0/16 | 1/20 | 0/4 | 0/14 | 0/23 | 0/23 |
| Dry mouthGastrointestinal disorders | 0/16 | 1/20 | 0/4 | 0/14 | 1/23 | 0/23 |
| NauseaGastrointestinal disorders | 0/16 | 1/20 | 0/4 | 0/14 | 1/23 | 0/23 |
| VomitingGastrointestinal disorders | 0/16 | 0/20 | 0/4 | 0/14 | 1/23 | 0/23 |
The safety population consisted of all patients who received study drug.
| Age, Continuous(Years) | Part A-30 mcg BXCL501 | Part A-60 mcg BXCL501 | Part A- 90 mcg BXCL501 | Part A-Placebo | Part B-40 Mcg-BXCL501 | Part B-Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 75.8 ± 8.0 | 77.7 ± 6.4 | 68.8 ± 7.9 | 75.9 ± 8.9 | 77.4 ± 8.2 | 77.3 ± 8.6 | 76.6 ± 8.0 |
| Sex: Female, Male(Participants) | Part A-30 mcg BXCL501 | Part A-60 mcg BXCL501 | Part A- 90 mcg BXCL501 | Part A-Placebo | Part B-40 Mcg-BXCL501 | Part B-Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 5 | 10 | 0 | 8 | 8 | 11 | 42 |
| Male | 11 | 10 | 4 | 6 | 15 | 12 | 58 |
| Ethnicity (NIH/OMB)(Participants) | Part A-30 mcg BXCL501 | Part A-60 mcg BXCL501 | Part A- 90 mcg BXCL501 | Part A-Placebo | Part B-40 Mcg-BXCL501 | Part B-Placebo | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 0 | 0 | 8 | 7 | 17 |
| Not Hispanic or Latino | 16 | 18 | 4 | 14 | 15 | 16 | 83 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A-30 mcg BXCL501 | Part A-60 mcg BXCL501 | Part A- 90 mcg BXCL501 | Part A-Placebo | Part B-40 Mcg-BXCL501 | Part B-Placebo | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 6 | 3 | 1 | 5 | 5 | 23 |
| White | 13 | 14 | 1 | 13 | 17 | 18 | 76 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2019 to primary completion in Jan 2022, 24 months.
Results were first posted in Sep 2023, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
BioXcel Therapeutics Inc